{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:00:48Z","timestamp":1784725248830,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.atherosclerosis.2011.04.018","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T14:00:17Z","timestamp":1303653617000},"page":"258-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["Clinical aspects of PCSK9"],"prefix":"10.1016","volume":"216","author":[{"given":"Bertrand","family":"Cariou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Le May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Costet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"November (47)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0005","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and Its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"issue":"August (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"May (5)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0015","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"December (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch Biochem Biophys"},{"issue":"May (5)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"September (37)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0030","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.0703402104","article-title":"The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain","volume":"104","author":"Hampton","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (5)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"issue":"January (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0040","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"issue":"October (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"April (25)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0050","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"issue":"April (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0055","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"February (6)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0060","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April (15)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0065","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (6)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0070","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (28)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0075","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"PCSK9-dependent LDL receptor regulation: effects of pH and LDL","volume":"282","author":"Fisher","year":"2007","journal-title":"J Biol Chem"},{"issue":"November (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0080","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"issue":"May (29)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0085","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"issue":"September (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem J"},{"issue":"September","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0095","article-title":"Annexin A2 is a C-terminal PCSK9 binding protein that regulates endogenous LDL receptor levels","author":"Mayer","year":"2008","journal-title":"J Biol Chem"},{"issue":"August (8)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0100","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"November (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0105","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J Lipid Res"},{"issue":"October (42)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0110","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J Biol Chem"},{"issue":"January (10)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0115","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J Biol Chem"},{"issue":"February (582(6))","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes","volume":"19","author":"Langhi","year":"2008","journal-title":"FEBS Lett"},{"issue":"February (15)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0125","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin\/kexin type 9","volume":"283","author":"Kourimate","year":"2008","journal-title":"J Biol Chem"},{"issue":"December (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0130","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"March (3)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0135","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1210\/en.2008-1281","article-title":"Importance of proprotein convertase subtilisin\/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors","volume":"150","author":"Persson","year":"2009","journal-title":"Endocrinology"},{"issue":"November (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0140","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1194\/jlr.P009860","article-title":"Fasting reduces plasma proprotein convertase, subtilisin\/kexin type 9 and cholesterol biosynthesis in humans","volume":"51","author":"Browning","year":"2010","journal-title":"J Lipid Res"},{"issue":"September (3)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0145","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.1152\/ajpendo.00166.2007","article-title":"Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol","volume":"293","author":"Galman","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"June (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"April (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"issue":"September (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2006.10.003","article-title":"Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic","volume":"194","author":"Tosi","year":"2007","journal-title":"Atherosclerosis"},{"issue":"November (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0165","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"issue":"May (9)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0170","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"March (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum Genet"},{"issue":"December (12)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0180","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1161\/01.ATV.0000190668.94752.ab","article-title":"Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response","volume":"25","author":"Naoumova","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"June (12)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0185","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of Familial Hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet"},{"issue":"November (5)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum Mutat"},{"issue":"September (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0195","first-page":"433","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2005","journal-title":"Atherosclerosis"},{"issue":"March (12)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"August (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0205","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.108.828467","article-title":"Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study","volume":"2","author":"Huang","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"March (5768)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0210","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1126\/science.1125884","article-title":"Lowering LDL\u2014not only how low, but how long?","volume":"311","author":"Brown","year":"2006","journal-title":"Science"},{"issue":"July (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2007.02.057","article-title":"Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study)","volume":"100","author":"Hallman","year":"2007","journal-title":"Am J Cardiol"},{"issue":"May (10)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0220","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2005.01.051","article-title":"A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis","volume":"45","author":"Chen","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"March (3)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"December (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20070150","article-title":"The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men","volume":"113","author":"Scartezini","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.atherosclerosis.2011.04.018_bib0235","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2350-7-66","article-title":"The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women","volume":"7","author":"Evans","year":"2006","journal-title":"BMC Med Genet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0240","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1515\/CCLM.2009.032","article-title":"The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan","volume":"47","author":"Hsu","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"January (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2009.06.023","article-title":"Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles","volume":"208","author":"Norata","year":"2010","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0250","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1371\/journal.pone.0001043","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke","volume":"2","author":"Abboud","year":"2007","journal-title":"PLoS ONE"},{"issue":"December (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0255","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","author":"Tarugi","year":"2007","journal-title":"Atherosclerosis"},{"issue":"December (12)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0260","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"March (3)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0265","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"September (3)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"April (16)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0275","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem"},{"issue":"October (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0280","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"March (6)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0285","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J Lipid Res"},{"issue":"April (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0290","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"supplt 1","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0295","first-page":"513","article-title":"Loss of the association between plasma pro-protein convertase subtilisin\/kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 diabetes","volume":"53","author":"Verges","year":"2010","journal-title":"Poster. Diabetologia"},{"issue":"December (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0300","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"issue":"July (7)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0305","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"July (9)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0310","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"issue":"January (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0315","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"issue":"February (6)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0320","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"issue":"December (12)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0325","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","article-title":"Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9","volume":"55","author":"Humphries","year":"2009","journal-title":"Clin Chem"},{"issue":"October (10)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0330","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"issue":"August (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0335","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.atherosclerosis.2010.04.015","article-title":"Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients","volume":"211","author":"Cariou","year":"2010","journal-title":"Atherosclerosis"},{"issue":"June (6)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0340","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"issue":"November (11)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0345","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1373\/clinchem.2009.128645","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?","volume":"55","author":"Chan","year":"2009","journal-title":"Clin Chem"},{"issue":"June (10)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0350","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1210\/en.2006-0098","article-title":"Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr","volume":"147","author":"Lambert","year":"2006","journal-title":"Endocrinology"},{"issue":"August (8)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0355","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"February (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0360","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"issue":"September (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0365","first-page":"246","volume":"212","author":"Costet","year":"2010","journal-title":"Winkler K. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients"},{"issue":"September (9)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0370","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"issue":"February (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0375","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"May (5)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0380","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"September (9)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0385","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1463-1326.2010.01229.x","article-title":"Fenofibrate concomitantly decreases serum proprotein convertase subtilisin\/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients","volume":"12","author":"Chan","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2011.04.018_bib0390","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"issue":"September (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0395","first-page":"345","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels","volume":"51","author":"Troutt","year":"2009","journal-title":"J Lipid Res"},{"issue":"September (9)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0400","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0149-2918(03)80281-3","article-title":"Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor","author":"Jeu","year":"2003","journal-title":"Clin Ther"},{"issue":"February (2)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0405","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.abb.2007.11.009","article-title":"Diabetes alters LDL receptor and PCSK9 expression in rat liver","volume":"470","author":"Niesen","year":"2008","journal-title":"Arch Biochem Biophys"},{"issue":"December (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0410","first-page":"701","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2009","journal-title":"FEBS Lett"},{"issue":"September (1)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0415","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2009.02.012","article-title":"Cellular and secreted pro-protein convertase subtilisin\/kexin type 9 catalytic activity in hepatocytes","volume":"206","author":"Kourimate","year":"2009","journal-title":"Atherosclerosis"},{"issue":"August (33)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0420","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April (4)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0425","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0430","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS ONE"},{"issue":"May (24)","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0435","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"October","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0440","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol","author":"Ni","year":"2010","journal-title":"J Lipid Res"},{"issue":"September 21","key":"10.1016\/j.atherosclerosis.2011.04.018_bib0445","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2007.07.029","article-title":"Plasma PCSK9 levels correlate with cholesterol in men but not in women","volume":"361","author":"Mayne","year":"2007","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011003601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011003601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:32:24Z","timestamp":1758155544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915011003601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0021915011003601"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.018","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical aspects of PCSK9","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}